Trials / Unknown
UnknownNCT05408546
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
Evaluation of the Safety and Thrombolytic Effects of Ascending Doses of TS23 in Subjects With Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Translational Sciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase II trial of TS23
Detailed description
Evaluation of safety and thrombolytic effect of ascending doses of TS23 in subjects with intermediate-risk (sub-massive) acute pulmonary embolism (PE)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TS23 | Monoclonal antibody to a2-antiplasmin |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2023-05-24
- Primary completion
- 2024-07-01
- Completion
- 2024-09-01
- First posted
- 2022-06-07
- Last updated
- 2023-07-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05408546. Inclusion in this directory is not an endorsement.